“We are the world leader in exploring brain metabolism with the goal of discovering new therapies.“

Frédéric Sedel, 2017

Read more about us
News

November 09th, 2018

MedDay Pharmaceuticals Announces Full Patient Enrollment for MD1003 Phase III Clinical Trial (SPI2) in Progressive Multiple Sclerosis
Read more

July 26th, 2018

MedDay Appoints Industry Leader Christian Chavy as Chief Executive Officer
Read more

October 18th, 2017

MedDay to Participate in the 7th Joint ECTRIMS – ACTRIMS Meeting in Paris, France
Read more

Careers

Committed to patients, our passionate teams are investigating brain metabolism therapies, utilizing an innovative approach, with the goal of transforming the lives of patients with serious neurological conditions.